On Friday 17 June the European Medicines Agency hosted a workshop on the changes to the safety-monitoring of medicines in Europe. The meeting heard feedback and the expectations of patients, consumer groups, healthcare professionals and the pharmaceutical industry.
The day long meeting was introduced by Andreas Pott the acting Executive Director of the European Medicines Agency (EMA). He expressed concern that the implementation of pharmacovigilance legislation may be delayed due to budgetary constraints, particularly in light of the recent vote of the European Parliament not to grant the discharge of the EMA’s 2009 budget due to concerns about conflict of interests and procurement procedures.
Within the EMA the technical and complicated implementation now has approximately 60 people attending a Cross Agency Task Force on the implementation of the directive and regulation. ICT tools are very important to the implementation and are being rapidly developed in conjunction with colleagues in order to avoid duplication. The EMA’s governance structure will be developed in line with the new legislation. A new committee, the Pharmacovigilance and Risk Assesment Committee will be created to advise the Committee for Medicinal Products for Human Use on pharmacovigilance related questions, and also to update the list of medicines subject to additional monitoring. The Committee will aim to be very transparant with minutes and agendas publicly available.
The new pharamcovigilance legislation allows for greater patient involvement in the safety monitoring of medicines. Patients will be able to directly report adverse reactions online and will be able to participate in public hearings in the case of potential problems. It is hoped that the public hearings will increase understanding of what the EMA does and increase stakeholder involvement. The circumstances under which a public hearing would be held are still under discussion. Presentations were given by patients, health professionals, and an academic on direct reporting in the UK.
Related EPHA articles
[->4372]
[->3920]
[->3725]
